Breaking News
Sort by:
Top Post
Vaxzevria Approved in the EU as Third Dose Booster Against COVID-19
AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the […]
Covalab Invests More Than €1 Million in Bioproduction Operations for Antibodies for Covid-19 Diagnostics
Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and […]
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 Ag Ultra […]
Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a […]
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new […]
AstraZeneca Signs Licence Agreement With RQ Biotechnology for Monoclonal Antibodies Against COVID-19
AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a […]
RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies
RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology […]
LifeArc Co-founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth Up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2
LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed […]
Roche Enters Partnership With the Global Fund to Support Low- and Middle-income Countries in Strengthening Critical Diagnostics Infrastructure
Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Global Fund […]
Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more